Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

NINDS

Drug and asset intelligence for NINDS with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Mechanism of action

Gene Therapy

Recent signals(1)

ClinicalJune 20, 2026

Gene Transfer Study for Giant Axonal Neuropathy Initiated by NINDS

A clinical trial has been initiated to evaluate the safety and potential efficacy of scAAV9/JeT-GAN for treating Giant Axonal Neuropathy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— NINDS

Key milestones include participant enrollment rates and initial safety data after the gene transfer procedure.

June 20, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Gene Therapy →
Neurology →
Neurology · Gene Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.